RiboX Therapeutics is a biotechnology company based in Shanghai, China, with a U.S. office in Princeton, New Jersey. It focuses on developing circular RNA (circRNA) therapies, a next-generation genetic medicine platform designed to provide longer-lasting and more stable protein expression than traditional mRNA therapies. Founded on the research of leading RNA scientists, RiboX aims to treat chronic and underserved diseases. The company is the first in the world to begin human trials of a circRNA therapy, marking a significant milestone in the field.